



EXAMPLE REPORT · DEMONSTRATION ONLY

REPORT CODE VTX-SPEC-1MEN-DEM0-2025	TESTING ORDERED 18 Jun 2026	SAMPLE RECEIVED 19 Jun 2026	DATE OF ANALYSIS 23 Jun 2026
--	--------------------------------	--------------------------------	---------------------------------

SAMPLE IDENTIFICATION



Client	Confidential client
Compound	Semaglutide (5 mg) – Lyophilised Powder
Manufacturer	Undisclosed
Batch / lot	SPC-SEMA05-2406
Appearance	White lyophilised cake, 5 mg vial, sealed under nitrogen. No visible particulates or discolouration on receipt.

ANALYSIS REQUESTED

Full analytical panel: Purity (HPLC), Identity (LC-MS), Peptide Content, Water Content, Acetate Content, Endotoxin (LAL), Sterility, Heavy metals (ICP-MS).

RESULTS

Overall result – PASS Sample meets all reported specifications

TEST	METHOD	RESULT	SPECIFICATION	STATUS
Purity (HPLC)	RP-HPLC / UV	98.7%	≥ 95.0%	PASS
Identity (LC-MS)	ESI-MS	Confirmed	MW ± 1 Da	PASS
Peptide Content	Gravimetric	86.5%	≥ 75.0%	PASS
Water Content	Karl Fischer	3.8%	≤ 8.0%	PASS
Acetate Content	IC	5.9%	≤ 15.0%	PASS
Endotoxin	LAL	< 0.5 EU/mg	< 5.0 EU/mg	PASS
Sterility	Membrane filtration	No growth	≤ 10 CFU/g	PASS
Heavy metals (As/Cd/Pb/Hg)	ICP-MS	Not detected	Within limits	PASS

PURITY (HPLC)  
**98.7%**

IDENTITY  
**Confirmed**

METHODS APPLIED  
RP-HPLC · LC-MS · KF · IC · LAL · ICP-MS

ANALYST COMMENTS

Sample meets all specifications. No significant impurities detected. This is an example certificate, provided to show the standard Veridan report layout.

AUTHORISED BY  
**V. Lab**  
Analytical Lead · Bridge Labs  
Analysis conducted 23 Jun 2026

VERIFY THIS CERTIFICATE  
**VTX-SPEC-1MEN-DEM0-2025**  
bridgeanalytical.com/verify

